Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
To read the full story
Related Article
- Choseido’s Kawauchi Plant Suspended for 1 Month on GMP Violation
March 28, 2025
- Choseido Violates GMP Once Again with Cefdinir, More Cases Being Probed
May 27, 2024
- Choseido Revamps Management, Sacks President Harada over GMP Violations
October 26, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- Lack of Management Response, Tight Manufacturing Plans to Blame in Choseido Issue: Report
October 12, 2021
- Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
- JGA Vows Strict Response to Choseido’s Biz Suspension Order
October 12, 2021
- Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
BUSINESS
- FRONTEO, Daiichi Sankyo Expand AI Collaboration into Toxicity Data Analysis
August 20, 2025
- PPIs Prescribed to 6.38 Million in July, Two APIs Control 60%: Intage
August 20, 2025
- FDA Pushes Back Decision on Hunter Syndrome Gene Therapy
August 20, 2025
- Santen Secures Asia Rights to RemeGen’s VEGF/FGF Eye Drug RC28-E
August 20, 2025
- Foreign Pharma Sales in Japan Projected to Rise 1.8% in 2025: Fuji Keizai
August 20, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…